trending Market Intelligence /marketintelligence/en/news-insights/trending/JCihUlaJzrWS-zKqx1peGQ2 content esgSubNav
In This List

DelMar's lead drug candidate secures US FDA's fast track status

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Video

S&P Capital IQ Pro | Powering Your Edge

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


DelMar's lead drug candidate secures US FDA's fast track status

DelMar Pharmaceuticals Inc. secured the U.S. Food and Drug Administration's fast track designation for VAL-083, its lead product candidate to treat a rare type of brain cancer.

VAL-083, also known as dianhydrogalactitol, is a DNA-targeting agent being developed as a treatment for recurrent glioblastoma.

The status applies to two ongoing clinical trials evaluating the treatment.

Separate from those trials, VAL-083 is also being investigated in patients newly diagnosed with a type of brain cancer known as MGMT-unmethylated glioblastoma and patients with recurrent platinum-resistant ovarian cancer.